← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
OIMAU
OneIM Acquisition Corp.
Valuation N/A
Financial Services
Price$10.21
Model IV—
P/IV—
Limited data — see page
OIMAW
OneIM Acquisition Corp.
Valuation N/A
Financial Services
Price$0.79
Model IV—
P/IV—
Limited data — see page
OKUR
OnKure Therapeutics, Inc.
Valuation N/A
Healthcare Risk 36 · Moderate
Price$2.93
Model IV—
P/IV—
Limited data — see page
OKYO
OKYO Pharma Ltd
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.40
Model IV—
P/IV—
Limited data — see page
OLB
OLB GROUP, INC.
Valuation N/A
Technology Risk 46 · Elevated
Price$0.28
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
OLMA
Olema Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$10.22
Model IV—
P/IV—
Limited data — see page
OLOX
OLENOX INDUSTRIES INC.
Valuation N/A
Industrials Risk 74 · High
Price$0.81
Model IV—
P/IV—
Market implies +19.9%/yr vs model +0.0% · above model
OM
Outset Medical, Inc.
Valuation N/A
Healthcare Risk 48 · Elevated
Price$3.21
Model IV—
P/IV—
Limited data — see page
OMAB
Central North Airport Group
Valuation N/A
Industrials
Price$98.73
Model IV—
P/IV—
Limited data — see page
OMER
OMEROS CORP
Valuation N/A
Healthcare Risk 59 · Elevated
Price$18.28
Model IV—
P/IV—
Limited data — see page
OMEX
ODYSSEY MARINE EXPLORATION INC
Valuation N/A
Industrials Risk 33 · Moderate
Price$0.72
Model IV—
P/IV—
Market implies +80.0%/yr vs model +2.0% · above model
OMSE
OMS Energy Technologies Inc.
Valuation N/A
Industrials Risk 29 · Moderate
Price$4.43
Model IV—
P/IV—
Limited data — see page
ON
ON SEMICONDUCTOR CORP
Valuation N/A
Technology Risk 38 · Moderate
Price$76.14
Model IV—
P/IV—
Market implies +23.0%/yr vs model +4.9% · above model
ONCH
1RT Acquisition Corp.
Valuation N/A
Financial Services
Price$10.32
Model IV—
P/IV—
Limited data — see page
ONCHU
1RT Acquisition Corp.
Valuation N/A
Financial Services
Price$10.44
Model IV—
P/IV—
Limited data — see page
ONCHW
1RT Acquisition Corp.
Valuation N/A
Financial Services
Price$0.49
Model IV—
P/IV—
Limited data — see page
ONCY
ONCOLYTICS BIOTECH INC
Valuation N/A
Healthcare Risk 37 · Moderate
Price$0.75
Model IV—
P/IV—
Limited data — see page
ONDS
Ondas Inc.
Valuation N/A
Technology Risk 37 · Moderate
Price$7.23
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
ONIT
ONITY GROUP INC.
Valuation N/A
Financial Services Risk 58 · Elevated
Price$34.34
Model IV—
P/IV—
Market implies +23.2%/yr vs model +7.9% · above model
ONMD
OneMedNet Corp
Valuation N/A
Industrials Risk 45 · Elevated
Price$0.65
Model IV—
P/IV—
Market implies +63.7%/yr vs model +15.0% · above model
ONMDW
OneMedNet Corp
Valuation N/A
Industrials Risk 59 · Elevated
Price$0.03
Model IV—
P/IV—
Market implies +15.0%/yr vs model +2.0% · above model
ONON
On Holding AG
Valuation N/A
Consumer Cyclical Risk 32 · Moderate
Price$27.47
Model IV—
P/IV—
Limited data — see page
ONTO
ONTO INNOVATION INC.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$281.26
Model IV—
P/IV—
Market implies +30.8%/yr vs model +3.0% · above model
OPFI
OppFi Inc.
Valuation N/A
Financial Services Risk 38 · Moderate
Price$7.98
Model IV—
P/IV—
Market implies -50.0%/yr vs model +13.2% · below model
OPP
RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.
Valuation N/A
Unknown
Price$7.36
Model IV—
P/IV—
Limited data — see page
OPRA
Opera Ltd
Valuation N/A
Technology Risk 31 · Moderate
Price$18.30
Model IV—
P/IV—
Limited data — see page
OPTH
Optimi Health Corp.
Valuation N/A
Healthcare
Price$5.07
Model IV—
P/IV—
Limited data — see page
OPTX
SYNTEC OPTICS HOLDINGS, INC.
Valuation N/A
Healthcare Risk 53 · Elevated
Price$7.10
Model IV—
P/IV—
Market implies +47.4%/yr vs model +2.0% · above model
OPTXW
SYNTEC OPTICS HOLDINGS, INC.
Valuation N/A
Healthcare Risk 67 · High
Price$1.26
Model IV—
P/IV—
Limited data — see page
OR
OR Royalties Inc.
Valuation N/A
Basic Materials Risk 37 · Moderate
Price$36.03
Model IV—
P/IV—
Limited data — see page
ORA
ORMAT TECHNOLOGIES, INC.
Valuation N/A
Utilities Risk 64 · High
Price$94.89
Model IV—
P/IV—
Limited data — see page
ORGN
Origin Materials, Inc.
Valuation N/A
Basic Materials Risk 37 · Moderate
Price$0.95
Model IV—
P/IV—
Market implies +35.9%/yr vs model +0.0% · above model
ORIC
Oric Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$12.04
Model IV—
P/IV—
Limited data — see page
ORIO
Orion Digital Corp.
Valuation N/A
Financial Services Risk 32 · Moderate
Price$1.05
Model IV—
P/IV—
Limited data — see page
ORIQ
Origin Investment Corp I
Valuation N/A
Financial Services Risk 37 · Moderate
Price$10.34
Model IV—
P/IV—
Limited data — see page
ORIQU
Origin Investment Corp I
Valuation N/A
Financial Services Risk 42 · Elevated
Price$10.35
Model IV—
P/IV—
Limited data — see page
ORIQW
Origin Investment Corp I
Valuation N/A
Financial Services Risk 61 · High
Price$0.11
Model IV—
P/IV—
Limited data — see page
ORKA
Oruka Therapeutics, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$92.20
Model IV—
P/IV—
Limited data — see page
ORLA
Orla Mining Ltd.
Valuation N/A
Basic Materials Risk 27 · Moderate
Price$9.44
Model IV—
P/IV—
Limited data — see page
ORMP
ORAMED PHARMACEUTICALS INC.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$4.62
Model IV—
P/IV—
Market implies +85.4%/yr vs model +2.0% · above model
OSCR
Oscar Health, Inc.
Valuation N/A
Financial Services Risk 40 · Elevated
Price$32.77
Model IV—
P/IV—
Limited data — see page
OSRH
OSR Holdings, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.20
Model IV—
P/IV—
Market implies +10.9%/yr vs model +15.0% · below model
OSS
ONE STOP SYSTEMS, INC.
Valuation N/A
Technology Risk 44 · Elevated
Price$9.19
Model IV—
P/IV—
Market implies +58.3%/yr vs model +2.0% · above model
OSTX
OS Therapies Inc
Valuation N/A
Healthcare Risk 34 · Moderate
Price$1.68
Model IV—
P/IV—
Limited data — see page
OSUR
ORASURE TECHNOLOGIES INC
Valuation N/A
Healthcare Risk 41 · Elevated
Price$3.25
Model IV—
P/IV—
Market implies +17.8%/yr vs model +2.0% · above model
OTF
Blue Owl Technology Finance Corp.
Valuation N/A
Unknown Risk 49 · Elevated
Price$10.63
Model IV—
P/IV—
Limited data — see page
OTGA
OTG Acquisition Corp. I
Valuation N/A
Financial Services
Price$10.23
Model IV—
P/IV—
Limited data — see page
OTGAU
OTG Acquisition Corp. I
Valuation N/A
Financial Services
Price$10.37
Model IV—
P/IV—
Limited data — see page
OTGAW
OTG Acquisition Corp. I
Valuation N/A
Financial Services
Price$0.35
Model IV—
P/IV—
Limited data — see page
OTLK
Outlook Therapeutics, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$0.66
Model IV—
P/IV—
Market implies +42.2%/yr vs model +15.0% · above model
OTLY
Oatly Group AB
Valuation N/A
Consumer Defensive Risk 42 · Elevated
Price$12.71
Model IV—
P/IV—
Limited data — see page
OUST
Ouster, Inc.
Valuation N/A
Industrials Risk 42 · Elevated
Price$35.33
Model IV—
P/IV—
Market implies +43.3%/yr vs model +49.9% · below model
OVID
Ovid Therapeutics Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$2.71
Model IV—
P/IV—
Market implies +75.8%/yr vs model +2.0% · above model
OWLS
OBOOK HOLDINGS INC.
Valuation N/A
Technology
Price$5.45
Model IV—
P/IV—
Limited data — see page
OXLC
Oxford Lane Capital Corp.
Valuation N/A
Unknown
Price$9.57
Model IV—
P/IV—
Limited data — see page
OXLCG
Oxford Lane Capital Corp.
Valuation N/A
Unknown
Price$24.88
Model IV—
P/IV—
Limited data — see page
OXLCI
Oxford Lane Capital Corp.
Valuation N/A
Unknown
Price$25.76
Model IV—
P/IV—
Limited data — see page
OXLCL
Oxford Lane Capital Corp.
Valuation N/A
Unknown
Price$24.38
Model IV—
P/IV—
Limited data — see page
OXLCM
Oxford Lane Capital Corp.
Valuation N/A
Unknown
Price$25.06
Model IV—
P/IV—
Limited data — see page
OXLCN
Oxford Lane Capital Corp.
Valuation N/A
Unknown
Price$24.58
Model IV—
P/IV—
Limited data — see page